179 related articles for article (PubMed ID: 33374592)
1. The Association between Ranitidine Use and Gastrointestinal Cancers.
McGwin G
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33374592
[TBL] [Abstract][Full Text] [Related]
2. Ranitidine Use and Risk of Upper Gastrointestinal Cancers.
Adami HO; Trolle Andersen I; Heide-Jørgensen U; Chang ET; Nørgaard M; Sørensen HT
Cancer Epidemiol Biomarkers Prev; 2021 Dec; 30(12):2302-2308. PubMed ID: 34620629
[TBL] [Abstract][Full Text] [Related]
3. No association between chronic use of ranitidine, compared with omeprazole or famotidine, and gastrointestinal malignancies.
Kim YD; Wang J; Shibli F; Poels KE; Ganocy SJ; Fass R
Aliment Pharmacol Ther; 2021 Sep; 54(5):606-615. PubMed ID: 34251045
[TBL] [Abstract][Full Text] [Related]
4. Effect of Oral Ranitidine on Urinary Excretion of N-Nitrosodimethylamine (NDMA): A Randomized Clinical Trial.
Florian J; Matta MK; DePalma R; Gershuny V; Patel V; Hsiao CH; Zusterzeel R; Rouse R; Prentice K; Nalepinski CG; Kim I; Yi S; Zhao L; Yoon M; Selaya S; Keire D; Korvick J; Strauss DG
JAMA; 2021 Jul; 326(3):240-249. PubMed ID: 34180947
[TBL] [Abstract][Full Text] [Related]
5. In Vitro Analysis of N-Nitrosodimethylamine (NDMA) Formation From Ranitidine Under Simulated Gastrointestinal Conditions.
Gao Z; Karfunkle M; Ye W; Marzan TA; Yang J; Lex T; Sommers C; Rodriguez JD; Han X; Florian J; Strauss DG; Keire DA
JAMA Netw Open; 2021 Jun; 4(6):e2118253. PubMed ID: 34181009
[TBL] [Abstract][Full Text] [Related]
6. Pharmacoepidemiological Research on N-Nitrosodimethylamine-Contaminated Ranitidine Use and Long-Term Cancer Risk: A Population-Based Longitudinal Cohort Study.
Wang CH; Chen II; Chen CH; Tseng YT
Int J Environ Res Public Health; 2022 Sep; 19(19):. PubMed ID: 36231768
[TBL] [Abstract][Full Text] [Related]
7. Risk of Cancer Following the Use of N-Nitrosodimethylamine (NDMA) Contaminated Ranitidine Products: A Nationwide Cohort Study in South Korea.
Yoon HJ; Kim JH; Seo GH; Park H
J Clin Med; 2021 Jan; 10(1):. PubMed ID: 33466237
[TBL] [Abstract][Full Text] [Related]
8. Oral intake of ranitidine increases urinary excretion of N-nitrosodimethylamine.
Zeng T; Mitch WA
Carcinogenesis; 2016 Jun; 37(6):625-634. PubMed ID: 26992900
[TBL] [Abstract][Full Text] [Related]
9. A Bioanalytical Method for Quantification of N-nitrosodimethylamine (NDMA) in Human Plasma and Urine with Different Meals and following Administration of Ranitidine.
De Palma R; Patel V; Florian J; Keire D; Selaya D; Strauss DG; Rouse R; Matta MK
J Pharm Sci; 2023 May; 112(5):1315-1323. PubMed ID: 36736776
[TBL] [Abstract][Full Text] [Related]
10. Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database.
Altebainawi AF; Alfaraj LA; Alharbi AA; Alkhuraisi FF; Alshammari TM
Ther Adv Drug Saf; 2023; 14():20420986231154075. PubMed ID: 36875514
[TBL] [Abstract][Full Text] [Related]
11. Prescription changes in patients with gastrointestinal disorders after withdrawal of ranitidine: a nationwide population-based cohort study.
Ku M; Je NK
Curr Med Res Opin; 2023 Feb; 39(2):197-203. PubMed ID: 36519289
[TBL] [Abstract][Full Text] [Related]
12. Understanding and Preventing (
White CM
Ann Pharmacother; 2020 Jun; 54(6):611-614. PubMed ID: 31771343
[No Abstract] [Full Text] [Related]
13. Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS).
Omar NE; Fahmy Soliman AI; Eshra M; Saeed T; Hamad A; Abou-Ali A
ESMO Open; 2021 Dec; 6(6):100315. PubMed ID: 34864500
[TBL] [Abstract][Full Text] [Related]
14. N-Nitrosodimethylamine (NDMA) Formation from Ranitidine Impurities: Possible Root Causes of the Presence of NDMA in Ranitidine Hydrochloride.
Yokoo H; Yamamoto E; Masada S; Uchiyama N; Tsuji G; Hakamatsuka T; Demizu Y; Izutsu KI; Goda Y
Chem Pharm Bull (Tokyo); 2021; 69(9):872-876. PubMed ID: 34470951
[TBL] [Abstract][Full Text] [Related]
15. N-nitrosodimethylamine (NDMA) contamination of ranitidine products: A review of recent findings.
Aldawsari FS; Alshehry YM; Alghamdi TS
J Food Drug Anal; 2021 Mar; 29(1):39-45. PubMed ID: 35696227
[TBL] [Abstract][Full Text] [Related]
16. Exposure to Ranitidine and Risk of Bladder Cancer: A Nested Case-Control Study.
Cardwell CR; McDowell RD; Hughes CM; Hicks B; Murchie P
Am J Gastroenterol; 2021 Aug; 116(8):1612-1619. PubMed ID: 34028367
[TBL] [Abstract][Full Text] [Related]
17. Determination of
Liu J; Zhao Z; Yang X; Jin Y; Liu X; Wang C; Zhang Z
Iran J Pharm Res; 2021; 20(4):255-264. PubMed ID: 35194444
[TBL] [Abstract][Full Text] [Related]
18. Pharmacists are key in interpreting clinical implications of N-nitrosodimethylamine contamination in medications.
Eads AV
J Am Pharm Assoc (2003); 2020; 60(6):e100-e104. PubMed ID: 32741598
[TBL] [Abstract][Full Text] [Related]
19. Ranitidine and Risk of Bladder and Kidney Cancer: A Population-Based Cohort Study.
Nørgaard M; Andersen IT; Heide-Jørgensen U; Erichsen R; Rees JR; Karagas MR; Sørensen HT
Cancer Epidemiol Biomarkers Prev; 2022 Jan; 31(1):45-50. PubMed ID: 34649959
[TBL] [Abstract][Full Text] [Related]
20. Temperature-Dependent Formation of N-Nitrosodimethylamine during the Storage of Ranitidine Reagent Powders and Tablets.
Abe Y; Yamamoto E; Yoshida H; Usui A; Tomita N; Kanno H; Masada S; Yokoo H; Tsuji G; Uchiyama N; Hakamatsuka T; Demizu Y; Izutsu KI; Goda Y; Okuda H
Chem Pharm Bull (Tokyo); 2020 Oct; 68(10):1008-1012. PubMed ID: 32779580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
